Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping kidney cancer: new radiation study aims to avoid surgery

NCT ID NCT02811250

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This early-phase study tested stereotactic radiotherapy, a precise type of radiation, on 13 people with small kidney cancers (≤4 cm). The goal was to find the highest safe dose by gradually increasing the radiation in four steps. Participants were followed for up to 5 years to monitor side effects. If proven safe and effective, this approach could offer a quick, non-surgical treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stereotactic radiotherapy (high-precision radiation)
What this could lead to
If successful, this could point toward a non-invasive, painless alternative to surgery for small kidney cancers.
What could go wrong
This is a very early, small phase I trial with only 13 participants, so results may not apply to all patients. The main goal is safety, not yet effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Oct 2010

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

75 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged over 75 years with an operable renal tumor or patient with inoperable renal tumor irrespective of age, or patient with metastatic renal tumor and indication for nephrectomy. * Histologically-confirmed Renal carcinoma less than or equal to 4 cm * Tumor that is visible and measureable on abdominal scanner and/or MRI (Magnetic Resonance Imaging) * Karnofsky performance status ≥ 60% Exclusion Criteria: * Patient with only one kidney and renal cancer * Patient not able to cooperate during treatment * Previous history of abdominal radiation therapy * Tumor having infiltrated the renal pelvis * Polycystic kidney disease * Previous history of intestinal inflammatory disease such as ulcerative colitis or Crohn's disease * Renal insufficiency (creatinine clearance \<30 ml/mm evaluated by DTPA (diethylenetriamine pentaacetic acid ) scintigraphy) * Uncontrolled hypertension (SBP(systolic blood pressure) above 160 mmHg DBP(diastolic blood pressure) above 100 mmHg with antihypertensive treatment) * Non primary lesions (benign lesions such as angiomyolipoma, renal metastases,…) * Antineoplastic and/or antiangiogenic treatment in the month preceding radiotherapy * Progressive cancer other than renal cancer at time of inclusion with the exception of in situ cervical carcinomas, basal cell carcinoma of the skin, and non-metastatic prostate cancer controlled without hormone therapy * Participation in another ongoing study that may interfere with the present study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cancer

Contacts and locations

Locations

  • Service d'Oncologie-Radiothérapie - Centre Hospitalier Lyon Sud - HCL

    Pierre-Bénite, 69495, France

  • Service de Radiothérapie - Centre Georges François Leclerc

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.